Paper Details

  1. Home
  2. Paper Details

Pharmacokinetics and bioavailability of ergoloid mesylates.

Author: LehrR, McDonaldS, SchranH F

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Ergoloid mesylates were rapidly absorbed following oral administration, with peak levels reached in 0.6 to 1.3 hours. Food slowed absorption but did not affect the overall amount absorbed. The sublingual tablet formulation did not provide improved bioavailability compared to the swallowed tablet.
Paper Details　
Original Abstract of the Article :
The pharmacokinetics and bioavailability of ergoloid mesylates following single administrations of various dose levels (3-9 mg), dosage forms (oral swallow and sublingual tablets, solution) and under different dosing conditions (fasted, with meal) were studied in young healthy volunteers. Male and f...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/bod.2510090404

データ提供：米国国立医学図書館（NLM）

Ergoloid Mesylates: Pharmacokinetics and Bioavailability

This research delves into the pharmacokinetics and bioavailability of ergoloid mesylates, a medication used for treating cognitive impairment associated with dementia. The study examines the absorption, distribution, metabolism, and elimination of ergoloid mesylates after single administrations of various dose levels, dosage forms, and under different dosing conditions. The findings provide valuable insights into the pharmacokinetic profile of ergoloid mesylates, informing optimal dosing strategies and understanding its therapeutic effectiveness. The study also investigates the impact of food intake on the absorption of ergoloid mesylates.

Understanding the Pharmacokinetics of Ergoloid Mesylates

This study provides a comprehensive understanding of the pharmacokinetic profile of ergoloid mesylates, revealing its rapid absorption, elimination half-life, and the impact of food intake on its bioavailability. These insights are crucial for optimizing dosing strategies and ensuring effective treatment of cognitive impairment associated with dementia. The study's findings also inform the development of more efficient and effective dosage forms of ergoloid mesylates.

Optimizing Treatment for Cognitive Impairment

This research highlights the importance of understanding the pharmacokinetic properties of medications to optimize treatment outcomes. By carefully considering the absorption, distribution, metabolism, and elimination of ergoloid mesylates, healthcare professionals can tailor dosing strategies to maximize its effectiveness in treating cognitive impairment associated with dementia. The study's findings also underscore the importance of considering the impact of food intake on medication absorption to ensure optimal therapeutic response.

Dr.Camel's Conclusion

Just as a camel navigates a desert landscape with a careful understanding of its environment, healthcare professionals need to navigate the complex world of pharmacokinetics to optimize treatment outcomes. This study, like a desert guide providing valuable information about water sources and terrain, reveals the pharmacokinetic profile of ergoloid mesylates, guiding us towards more effective treatment strategies for cognitive impairment.

Date :
  1. Date Completed 1989-02-17
  2. Date Revised 2019-10-22
Further Info :

Pubmed ID

3207855

DOI: Digital Object Identifier

10.1002/bod.2510090404

Related Literature

Article Analysis
・Effects of ergoloid mesylates
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.